These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16608120)

  • 21. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
    Jensen PE; Sellebjerg F; Søndergaard HB; Sørensen PS
    Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
    Bartosik-Psujek H; Stelmasiak Z
    Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
    Ravnborg M; Bendtzen K; Christensen O; Jensen PE; Hesse D; Tovey MG; Sørensen PS
    Mult Scler; 2009 Mar; 15(3):323-8. PubMed ID: 19028832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients.
    Lam R; Farrell R; Aziz T; Gibbs E; Giovannoni G; Grossberg S; Oger J
    J Immunol Methods; 2008 Jul; 336(2):113-8. PubMed ID: 18511063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.
    Malucchi S; Capobianco M; Gilli F; Marnetto F; Caldano M; Sala A; Bertolotto A
    Neurol Sci; 2005 Dec; 26 Suppl 4():S213-4. PubMed ID: 16388361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells.
    Abdul-Ahad AK; Galazka AR; Revel M; Biffoni M; Borden EC
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):27-32. PubMed ID: 9287241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    Sorensen PS; Koch-Henriksen N; Bendtzen K
    Mult Scler; 2007 Jun; 13(5):616-21. PubMed ID: 17548440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
    Sominanda A; Rot U; Suoniemi M; Deisenhammer F; Hillert J; Fogdell-Hahn A
    Mult Scler; 2007 Mar; 13(2):208-14. PubMed ID: 17439886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.
    Weber F; Cepok S; Wolf C; Berthele A; Uhr M; Bettecken T; Buck D; Hartung HP; Holsboer F; Müller-Myhsok B; Hemmer B
    Pharmacogenomics J; 2012 Jun; 12(3):238-45. PubMed ID: 21502966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of a multiplex bead-based screening assay for detection of binding antibodies to interferon-beta.
    Lapé Nixon M; Matud J; Yeh C; Prince HE
    J Neuroimmunol; 2009 May; 210(1-2):104-7. PubMed ID: 19345423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    Vartanian T; Sölberg Sørensen P; Rice G
    J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
    Hurwitz BJ
    J Neurol Sci; 2008 Sep; 272(1-2):8-19. PubMed ID: 18620708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon inhibitory activity in patients with multiple sclerosis.
    Chadha K; Weinstock-Guttman B; Zivadinov R; Bhasi K; Muhitch J; Feichter J; Tamaño-Blanco M; Abdelrahman N; Ambrus J; Munschauer F; Ramanathan M
    Arch Neurol; 2006 Nov; 63(11):1579-84. PubMed ID: 17101826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
    Horowski R; Stürzebecher CS; Kapp JF
    Funct Neurol; 2001; 16(2):117-28. PubMed ID: 11495417
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessment and management of neutralizing antibodies in patients with multiple sclerosis.
    Hartung HP; Munschauer FE
    J Neurol; 2004 Jun; 251 Suppl 2():II40-2. PubMed ID: 15264111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
    Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
    J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Considerations on the development of serum antibodies to interferon-beta.
    Antonelli G; Bagnato F; Dianzani F
    New Microbiol; 2005 Jul; 28(3):183-92. PubMed ID: 16240689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.
    Santos R; Weinstock-Guttman B; Tamaño-Blanco M; Badgett D; Zivadinov R; Justinger T; Munschauer F; Ramanathan M
    J Neuroimmunol; 2006 Jul; 176(1-2):125-33. PubMed ID: 16698090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.
    Pachner AR; Dail D; Pak E; Narayan K
    J Neuroimmunol; 2005 Sep; 166(1-2):180-8. PubMed ID: 16005084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.